911 results match your criteria: "UCSF Helen Diller Family Comprehensive Cancer Center.[Affiliation]"
J Immunother Cancer
January 2025
Sonata Therapeutics Inc, Watertown, Massachusetts, USA
Cancer immunotherapy-including immune checkpoint inhibition (ICI) and adoptive cell therapy (ACT)-has become a standard, potentially curative treatment for a subset of advanced solid and liquid tumors. However, most patients with cancer do not benefit from the rapidly evolving improvements in the understanding of principal mechanisms determining cancer immune responsiveness (CIR); including patient-specific genetically determined and acquired factors, as well as intrinsic cancer cell biology. Though CIR is multifactorial, fundamental concepts are emerging that should be considered for the design of novel therapeutic strategies and related clinical studies.
View Article and Find Full Text PDFJ Natl Compr Canc Netw
January 2025
National Comprehensive Cancer Network.
Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous soft tissue sarcoma and affects an estimated 1,500 people annually in the United States. DFSP frequently exhibits extensive local infiltration. Initial treatment is through surgical excision, and care should be taken to ensure that negative margins are achieved to minimize recurrence.
View Article and Find Full Text PDFJ Natl Compr Canc Netw
January 2025
National Comprehensive Cancer Network.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening provide criteria for selecting individuals for screening and offer recommendations for evaluating and managing lung nodules detected during initial and subsequent annual screening. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Lung Cancer Screening.
View Article and Find Full Text PDFEndocr Relat Cancer
January 2025
E Bergsland, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States.
Grade progression of well differentiated pancreatic neuroendocrine tumors (panNETs) can occur over time, with G1/2 to G3 the most clinically relevant form. Here we conducted a retrospective cohort study of 66 patients with initially G1/2 panNET (median initial Ki67, 4.6%).
View Article and Find Full Text PDFJCO Oncol Pract
January 2025
Division of Allergy, Immunology and BMT, Department of Pediatrics, UCSF Benioff Children's Hospitals, San Francisco, CA.
CA Cancer J Clin
January 2025
Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco (UCSF), San Francisco, California, USA.
Despite ongoing efforts to increase the number of women in science, technology, engineering, and mathematics (STEM) and in medicine, Hispanic women remain severely underrepresented in these fields. This disparity not only hinders scientific innovation and the delivery of culturally competent medical care but also perpetuates a systemic exclusion. Research specifically addressing the challenges faced by Hispanic women, the extent of underrepresentation in these disciplines, and strategies to mitigate these issues is sparce.
View Article and Find Full Text PDFNat Med
January 2025
Department of Medicine-Medical Oncology, University of Colorado Cancer Center, Denver, CO, USA.
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy (n = 30) and in combination with atezolizumab (n = 183) in pretreated patients with advanced solid tumors.
View Article and Find Full Text PDFWomens Health Rep (New Rochelle)
December 2024
Department of Family Health Care Nursing, School of Nursing, University of California, San Francisco, California, USA.
J Clin Oncol
January 2025
Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ann Oncol
December 2024
Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
J Natl Compr Canc Netw
December 2024
National Comprehensive Cancer Network.
Multigene panel testing has allowed for the detection of a growing number of inherited pathogenic/likely pathogenic variants in people at high risk of cancer, including endometrial cancer (EC). Hereditary syndromes associated with EC include Lynch syndrome, PTEN hamartoma tumor syndrome, and Peutz-Jeghers syndrome. This manuscript provides the latest recommendations from the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric on the screening and management of EC in patients at high risk for these syndromes, as well as the advantages and limitations of multigene panel testing.
View Article and Find Full Text PDFJ Natl Compr Canc Netw
December 2024
National Comprehensive Cancer Network.
The NCCN Guidelines for Survivorship include recommendations for screening, evaluation, and treatment of psychosocial and physical problems resulting from adult-onset cancer and its treatment. They also include recommendations to promote healthy behaviors and immunizations in survivors and provide a framework for care coordination. These NCCN Guidelines Insights summarize the panel's current recommendations regarding sexual health and fertility.
View Article and Find Full Text PDFNature
January 2025
Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
The ability of cells to maintain distinct identities and respond to transient environmental signals requires tightly controlled regulation of gene networks. These dynamic regulatory circuits that respond to extracellular cues in primary human cells remain poorly defined. The need for context-dependent regulation is prominent in T cells, where distinct lineages must respond to diverse signals to mount effective immune responses and maintain homeostasis.
View Article and Find Full Text PDFCancer Discov
December 2024
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
Effective therapies for pancreatic ductal adenocarcinoma (PDAC) have been largely elusive. Here, we perform Multiplexed kinase Inhibitor Bead Mass Spectrometry on 102 patient derived xenografts derived from 14 unique primary PDAC to define the tumor-intrinsic kinome landscape. Our findings uncover three kinome subgroups making up two tumor-intrinsic kinome subtypes that we call kinotypes.
View Article and Find Full Text PDFEur Urol
November 2024
Departments of Urology and Epidemiology & Biostatistics, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. Electronic address:
Cancer Epidemiol
February 2025
Center for Research on Population Health, National Institute of Public Health, Mexico City, Mexico; Department of Global Health and Population, Harvard T.H. Chan School of Public Health, USA. Electronic address:
J Nucl Med
January 2025
Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium; and.
J Natl Compr Canc Netw
November 2024
2Department of Dermatology, Havard Medical School, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.
Ann Oncol
November 2024
Department of Medicine, Center for BRCA Research, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA.
Estrogens have been associated with an increase in breast cancer risk. Yet emerging clinical and experimental evidence points to progestogens [endogenous progesterone or synthetic progesterone (progestin)] as the primary hormonal driver underlying seemingly estrogen-associated breast cancer risk. Estrogens may contribute to breast cancer risk indirectly by induction of the progesterone receptor and thus amplifying progesterone signaling.
View Article and Find Full Text PDFmedRxiv
October 2024
GROW - Research Institute for Oncology and Reproduction, Maastricht University; Maastricht, Netherlands.
Oncologist
October 2024
Department of Medicine, University of California, San Francisco, CA 94143, United States.
Can J Urol
October 2024
UCSF - Helen Diller Family Comprehensive Cancer Center University of California, San Francisco, USA.
Sci Rep
October 2024
NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
In cancer research, RAS biology has been focused on only a handful of tumor types. While RAS genes have long been suspected as common contributors to a wide spectrum of cancer types, robust evidence is required to firmly establish their critical oncogenic significance. We present a data mining study using DepMap genome-wide CRISPR screening data, which provide substantial evidence to support the prominent pervasive oncogenic role and tissue-specific permissiveness of RAS gene mutations.
View Article and Find Full Text PDFAddict Behav Rep
December 2024
The Center for Tobacco Control Research and Education, University of California, San Francisco, CA, United States.
Background: Research investigating the association between cigarette smoking and COVID-19 outcomes has yielded mixed results, often overlooking cannabis use. This study examined the association between cigarette smoking and COVID-19 hospitalization with consideration of cannabis use.
Methods: We used electronic health record data from adult patients with COVID-19 (2/1/2020 to 2/3/2022) at a northern California academic medical center.
Bone Marrow Transplant
January 2025
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.